Premium
A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial
Author(s) -
Tsai HueiTing,
Caroff Stanley N.,
Miller Del D.,
McEvoy Joseph,
Lieberman Jeffrey A.,
North Kari E.,
Stroup T. Scott,
Sullivan Patrick F.
Publication year - 2010
Publication title -
american journal of medical genetics part b: neuropsychiatric genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.393
H-Index - 126
eISSN - 1552-485X
pISSN - 1552-4841
DOI - 10.1002/ajmg.b.30981
Subject(s) - tardive dyskinesia , candidate gene , schizophrenia (object oriented programming) , antipsychotic , dyskinesia , psychosis , psychology , movement disorders , psychiatry , single nucleotide polymorphism , genetic association , medicine , genotype , genetics , gene , biology , parkinson's disease , disease
Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro‐facial, limb, and truncal movements. As a genetic basis for inter‐individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler–Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects—2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, and GABA pathways) and composite genotypes for 10 drug‐metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature. © 2009 Wiley‐Liss, Inc.